Hartford Business.com (01.09.2014)
Aids Weekly Plus
Hartford Business.com recently reported that the New Haven, Conn., biotech firm Melinta Therapeutics began Phase 3 trials of the drug deloflaxin to compare its safety and effectiveness in treating gonorrhea to existing treatments. According to a 2012 CDC report, new antibiotic treatments are needed to halt a four-fold increase in gonorrhea throughout the next seven years, since drug resistance has reduced the recommended treatment for the disease to just one combination of ceftriaxone and azithromyacin. During 2012, Congress signed into law the GAIN Act, which provides incentives to biotech firms that develop antibiotics for drug-resistant pathogens—if deloflaxin receives approval for gonorrhea treatment, the medication would receive 10 years of market exclusivity—double the usual timeframe.